The Data Surrounding the Legal Cannabis Markets

Friday, March 17, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 17, 2017 /PRNewswire/ -- News Commentary 

In a recent report by

Arcview Market Research, the legal cannabis market is arguably the fastest growing industry in the world. The data reported shows, that regulated cannabis sales in North America totaled $6.9 billion
in 2016, a 30 percent increase from 2015. Sales are projected to increase to $21.6 billion by the year 2021, representing a 26 percent compound annual growth rate. In Colorado, Washington, and Oregon, where cannabis products for recreational use were legalized before 2016, consumers spending on cannabis were up 62% between 2015 and September 2016., Inc. (OTC: CIIX), 22nd Century Group Inc. (NYSE: XXII), Medical Marijuana Inc. (OTC: MJNA), OWC Pharmaceuticals (OTC: OWCP), Through Terra Tech Corporation (OTC: TRTC)

As a result of the industry's growth, experts now expect a shift from sales on the black market, to gain steam in the legal cannabis market. "It's one of the major reasons that people are going to leave the underground market to go to the aboveground market. It's about variety," Arcview CEO Troy Dayton told Business Insider. "You just can't get these products on the underground market.", Inc. (OTCQB: CIIX) on February 1st announced, the launch of its new website for its new subsidiary The website went live on January 31st, under the URL:

The Company is expanding into the medical marijuana industry with the launch of its website, and plans to retail hemp oil and related products, which are legal to sell and distribute within China, and in the United States, in all fifty states (hemp oil is not marijuana, but indeed a separate and distinct plant made from hemp). CBD oil, derived from hemp is a product with medicinal qualities that are primarily used for anti-inflammatory and other common ailments.

Mr. Warren Wang, the Chairman of stated: "I am very pleased to see the investor reaction to our announced plans which we began to disclose over a month ago. Indeed the market has responded with very strong interest in our shares, and as a result, we have achieved record trading volume and reached a new fifty-two week high in our shares last week."

Plant biotechnology company, 22nd Century Group Inc. (NYSE: XXII), is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants, through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties, development of X-22, a smoking cessation aid consisting of very low nicotine cigarettes, manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes, production of SPECTRUM research cigarettes for the National Institute on Drug Abuse; contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol, plants with high levels of cannabidiol, and other non-THC cannabinoids.

Development-stage company that operates in the cannabis and industrial hemp space in America, Medical Marijuana Inc. (OTCQB: MJNA), announced that its subsidiary HempMeds® Mexico, had held a press conference in Mexico, to reveal the positive results of a recent study conducted by renowned Mexican physician, Dr. Saul Garza Morales, on the effects of the Company's Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy. The study, conducted by Mexican pediatric neurologist Dr. Garza, included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 7 reported a complete elimination of all seizures, over a 4-month period, with zero reported side effects.

OWC Pharmaceuticals (OTCQB: OWCP) is focused on the development of two delivery systems: A proprietary, cannabinoid-enriched sublingual tablet and a proprietary topical compound. The company developed its cannabinoid-enriched sublingual tablet for the administration of medical cannabis, near the end of last year. The tablet was developed to increase the bioavailability of cannabinoids and provide an optimal administration method for consistent dosing. The company plans to develop the tablet to treat conditions like multiple myeloma, post-traumatic stress disorder, and fibromyalgia. OWC Pharmaceuticals formulated a topical cannabinoid-based cream for the treatment of psoriasis, in partnership with Emilia Cosmetics Ltd., one of Israel's largest cosmetic manufacturers.

Through Terra Tech Corporation (OTCQX: TRTC) together with its subsidiaries, engages in the design, marketing, and sale of hydroponic equipment with proprietary technology, to create sustainable solutions for the cultivation of indoor agriculture in Newport Beach and Irvine, California. It operates through two segments: Hydroponic Produce and Cannabis Products. It also operates as a retail seller of hydroponic produce, herbs, and floral products, which are distributed in the Midwest and the Northeast United States; and produces and sells a line of cannabis flowers and cigarettes, as well as a line of cannabis pure concentrates, including oils, waxes, shatters, and clears to dispensaries in California.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, has been compensated three thousand dollars for financial news dissemination and pr services by inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a two year agreement with inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: E-mail: Phone: +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store